Literature DB >> 7509142

Inhibition of visna virus replication by 2',3'-dideoxynucleosides and acyclic nucleoside phosphonate analogs.

H Thormar1, J Balzarini, A Holy, J Jindrich, I Rosenberg, Z Debyser, J Desmyter, E De Clercq.   

Abstract

A series of acyclic nucleoside phosphonate (ANP) and 2',3'-dideoxynucleoside (ddN) derivatives were evaluated for their inhibitory effects on visna virus replication and maedi/visna virus-induced syncytium formation in sheep choroid plexus cells. Most ANP derivatives inhibited virus replication and syncytium formation within a concentration range of 0.2 to 1.8 microM. Among the most active ANP derivatives ranked (R)-9-(2-phosphonomethoxypropyl)adenine, (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine, and (S)-9-(3-fluoro-2-phosphonomethoxypropyl)adenine. Of the ddN derivatives, 2',3'-dideoxycytidine (ddCyd) proved to be the most inhibitory to visna virus-induced syncytium formation (50% effective concentration, 0.02 microM). The purine ddN analogs (i.e., 2',3'-dideoxyinosine, 2',3'-dideoxyadenosine, 2',3'-dideoxyguanosine, and 2,6-diaminopurine-2',3'-dideoxyribosine) were 10- to 30-fold less effective, and the thymidine derivatives 2',3'-didehydro-2',3'-dideoxythymidine (D4T) and 3'-azido-2',3'-dideoxythymidine (AZT) were more than 500-fold less inhibitory to visna virus than ddCyd. The 5'-triphosphate forms of AZT and D4T were 100- to 600-fold more inhibitory to visna virus particle-derived reverse transcriptase than was the 5'-triphosphate of ddCyd. The apparent discrepancy between the inhibitory effects of these ddN derivatives on virus replication and viral reverse transcriptase activity most likely reflects differences in the metabolic conversion of ddCyd versus D4T and AZT in sheep choroid plexus cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7509142      PMCID: PMC192732          DOI: 10.1128/AAC.37.12.2540

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  New acquisitions in the development of anti-HIV agents.

Authors:  E De Clercq
Journal:  Antiviral Res       Date:  1989-08       Impact factor: 5.970

2.  Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent.

Authors:  J Balzarini; L Naesens; P Herdewijn; I Rosenberg; A Holy; R Pauwels; M Baba; D G Johns; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides.

Authors:  K B Frank; P A McKernan; R A Smith; D F Smee
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

4.  Ribonucleic acid-dependent deoxyribonucleic acid polymerase in visna virus.

Authors:  F H Lin; H Thormar
Journal:  J Virol       Date:  1970-11       Impact factor: 5.103

5.  Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome.

Authors:  T W North; G L North; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

6.  Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds.

Authors:  J Balzarini; P Herdewijn; E De Clercq
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

7.  Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine.

Authors:  H Egberink; M Borst; H Niphuis; J Balzarini; H Neu; H Schellekens; E De Clercq; M Horzinek; M Koolen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

8.  Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents.

Authors:  R Pauwels; J Balzarini; D Schols; M Baba; J Desmyter; I Rosenberg; A Holy; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

9.  Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides.

Authors:  J E Dahlberg; H Mitsuya; S B Blam; S Broder; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

10.  Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine.

Authors:  J Balzarini; A Holy; J Jindrich; L Naesens; R Snoeck; D Schols; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

View more
  7 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 2.  In search of a selective antiviral chemotherapy.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

3.  Transport of 9-(2-phosphonomethoxyethyl)adenine across plasma membrane of HeLa S3 cells is protein mediated.

Authors:  T Cihlár; I Rosenberg; I Votruba; A Holý
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

4.  Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs.

Authors:  H Thormar; G Georgsson; P A Pálsson; J Balzarini; L Naesens; S Torsteinsdóttir; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

Review 5.  Acyclic nucleosides as antiviral compounds.

Authors:  S Freeman; J M Gardiner
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

6.  Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates.

Authors:  J Balzarini; C Pannecouque; E De Clercq; S Aquaro; C-F Perno; H Egberink; A Holý
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

7.  Multivalent interactions essential for lentiviral integrase function.

Authors:  Allison Ballandras-Colas; Vidya Chivukula; Dominika T Gruszka; Zelin Shan; Parmit K Singh; Valerie E Pye; Rebecca K McLean; Gregory J Bedwell; Wen Li; Andrea Nans; Nicola J Cook; Hind J Fadel; Eric M Poeschla; David J Griffiths; Javier Vargas; Ian A Taylor; Dmitry Lyumkis; Hasan Yardimci; Alan N Engelman; Peter Cherepanov
Journal:  Nat Commun       Date:  2022-05-03       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.